Amylyx Pharmaceuticals

The work to support the global #neurodegenerative disease community never stops. Subscribe for the latest updates from Amylyx at www.amylyx.com.

Our work, our motivation, and the core values that guide us are deeply interwoven. Learn more about each of the core values guiding #TeamAmylyx below.

Symptomatic post-bariatric hypoglycemia (#PBH) affects ~8% of people who have undergone bariatric surgery and occurs, on average, 1-3 years post-surgery. PBH is thought to be caused by an excessive glucagon-like peptide-1 (GLP-1) response leading to hypoglycemia and impaired quality of life. Learn more about PBH below.

Our work at Amylyx means we often confront the difficult truths of diseases with high unmet needs, including those of children living in families with ALS. We recently watched LUKi & the Lights (linked below) together as a team and found it a compassionate and honest depiction of ALS.    Our heartfelt thanks to Melinda Kavanaugh, PhD, LCSW, President of Global Neuro YCare and recent Amylyx Beyond the Diagnosis guest speaker, for sharing this animated film with us and empowering us to further raise awareness. Watch LUKi and the Lights here: https://lnkd.in/ed-uMxzq

We’re excited to return to the ALS ONE Research Symposium, joining others in industry to discuss current research that’s underway around the world. More details on Amylyx’ presentation below.

We’re looking forward to attending the Child Neurology Society (CNS) Annual Meeting next week in San Diego, where we’ll be sharing results from our HELIOS trial in #Wolframsyndrome. More details below. #CNSAM

Congratulations Cindy Goodman for becoming a Finalist at the 2024 Admin Awards. Thank you for all that you do for #TeamAmylyx!

We recently announced positive topline data from our open-label, Phase 2 HELIOS clinical trial in 12 adults with Wolfram syndrome. The study showed improvement in pancreatic function, as measured by C-peptide response after 24 weeks of treatment with our investigational therapy, the study’s primary efficacy endpoint, in contrast to the expected decrease in pancreatic function with disease progression.    To learn more about these results, watch our webinar, which is available here: https://bit.ly/40wTnLF

Earlier this week, our Chief Medical Officer, Camille Bedrosian, MD, joined a thought-provoking panel at the Longwood Healthcare Leaders Boston CEO Meeting that explored innovation in clinical trials and highlighted the vital role of patient-centricity. At Amylyx, our commitment to communities with high unmet needs drives us, and prioritizing their perspectives in our clinical trials is essential to driving meaningful progress and innovation. A sincere thank you to Longwood Healthcare Leaders and everyone who contributed to this impactful event.

We recently partnered with the Margaret Fuller Neighborhood House to create snack kits that will help families in the Greater Boston area. Thank you to the Amylyx team members who participated in this community give-back activity and who contribute to our culture of caring each and every day.